August 2, 2021 8:48 AM 29 seconds read

Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna

by Vandana Singh Benzinga Editor
Follow
Comments
  • Autolus Therapeutics plc AUTL has granted Moderna Inc MRNA an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.
  • Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments. 
  • In addition, Autolus would be entitled to receive royalties on net sales.
  • Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.
AUTL Logo
AUTLAutolus Therapeutics PLC
$1.91-3.79%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum6.07
Growth30.19
Quality-
Value9.65
Price Trend
Short
Medium
Long
Overview
MRNA Logo
MRNAModerna Inc
$35.100.26%
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareContractsSmall CapGeneralBriefscancermRNA vaccines

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved